Pharmacoepidemiologists - come work with us! @RutgersPETS@RutgersIFH
Open Rank Faculty Position, Rutgers Center for Pharmacoepidemiology and Treatment Science: https://t.co/Rf5ASy7kTE
@lauffenburgerjc @adherence_ispe @danielankrah45 @lauffenburgerjc Yes, I think so --- and opportunity to inquire about unknown medication use - ex. opioids and benzodiazepines #adherencejc
@adherence_ispe Yes I agree @lauffenburgerjc and I found the potential drug interactions findings interesting -- particularly when involving medications not in the EHR
@lauffenburgerjc @adherence_ispe Yes I agree. Within prevalent users I do like the idea of starting at a blood pressure measurement given this may represent a point when adherence interventions could be implemented #adherencejc
@adherence_ispe @SarahJoSinnott They did allow switching within and between drug classes... I’m sure calculating the pdc gets complicated quickly with multiple drugs within a class! #adherencejc
@adherence_ispe @lauffenburgerjc @DurandHannah I wasn’t entirely clear why it was restricted to patients with high adherence during baseline #adherencejc
@adherence_ispe The multiple aspects included in the intervention along with providing useful subgroup results, which could help improve this intervention when used in other populations #adherencejc
@adherence_ispe One challenge may be the individuals willing/wanting to participate were more likely to be adherent and partake in other healthy behaviors #adherencejc
@adherence_ispe I agree Julie! And while not statistically significant, there does seem to be a lot of potential with the intervention given cost reductions and 4% increase in mean PDC #adherencejc